REG - GSK PLC - EC approval of Shingrix PFS

GSKAnnouncement

Wed 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260107:nRSG8977Na&default-theme=true

RNS Number : 8977N  GSK PLC  07 January 2026

Issued: 7(th) January 2026, London UK

 

GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation
approved by the European Commission

 

·   Prefilled syringe offers healthcare professionals a convenient
administration option

·   New presentation will begin rolling out across EU countries in 2026

·   Shingles affects approximately 1.7 million people in Europe each
year, 1  (#_edn1) with certain chronic conditions linked to a higher risk of
shingles 2  (#_edn2) (,) 3  (#_edn3)

 

 

 

GSK plc (LSE/NYSE: GSK) today announced the European Commission's (EC)
approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in a prefilled
syringe. The current vaccine presentation comprises two vials, one with a
lyophilised powder antigen and another with a liquid adjuvant. The lyophilised
powder antigen requires reconstitution, where the suspension in the adjuvant
vial is withdrawn and injected into the antigen vial. The new prefilled
syringe simplifies the vaccine administration process for healthcare
professionals by removing the need to undertake these steps prior to
administration.

 

Tony Wood, Chief Scientific Officer, GSK, said: "This new presentation of
Shingrix has been designed to improve ease of administration, helping
healthcare professionals to provide protection against shingles. Shingles is a
painful disease that can have serious and long-lasting complications. It
affects millions of people each year in Europe, often imposing a greater
burden on people living with common chronic diseases such as cardiovascular
disease and diabetes. GSK is proud to support the healthcare community by
making administration of its shingles vaccine easier."

 

This approval is based on data confirming technical comparability between the
prefilled syringe and the existing vaccine presentation. 4  (#_edn4) The new
presentation does not involve a change in indication or dosing.

 

About shingles

Shingles is caused by the reactivation of the varicella-zoster virus (VZV),
the same virus that causes chickenpox.(2) Globally, up to 1 in 3 adults will
develop shingles in their lifetime.(2, 5  (#_edn5) , 6  (#_edn6) , 7  (#_edn7)
) Over 90% of adults have the VZV dormant in their nervous system, waiting to
reactivate.(2, 8  (#_edn8) , 9  (#_edn9) , 10  (#_edn10) ) In addition to
advancing age, chronic conditions like cardiovascular disease, chronic kidney
disease, chronic obstructive pulmonary disease, asthma, and diabetes are all
linked to higher risk of shingles.(2,3)

 

Shingles typically presents as a rash, with painful blisters across the chest,
abdomen or face.(8) Following the rash, up to 30% of people experience
post-herpetic neuralgia (PHN), 11  (#_edn11) a long-lasting nerve pain that
can last weeks or months and can occasionally persist for several years.(2)

 

About Shingrix (Recombinant Zoster Vaccine or RZV)

Shingrix combines an antigen, glycoprotein E, with an adjuvant system,
AS01(B), and may help overcome the natural age-related decline in responses to
immunisation that contributes to the challenge of protecting adults aged 50
and over from shingles. 12  (#_edn12) (, 13  (#_edn13) ) RZV is not indicated
to prevent primary varicella infection (chickenpox). The use of RZV should be
in accordance with official recommendations and local product label.

 

GSK's shingles vaccine has been approved in the European Union for the
prevention of herpes zoster (HZ) and PHN in adults aged 50 years or older
since 2018; and in adults 18 years or older at increased risk of HZ, since
2020.

 

Please refer to the Product Information (PI) for important dosage,
administration, and safety information in Europe available at this link:
https://www.ema.europa.eu/en/medicines/human/EPAR/shingrix

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(https://www.gsk.com) .

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Sam Piper          +44 (0) 7824 525779   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q3 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

References

 1  (#_ednref1) Pinchinat et al. Similar herpes zoster incidence across
Europe: results from a systematic literature review. BMC Infect Dis.
2013;13:170.

 2  (#_ednref2) Harpaz R, et al. Advisory Committee on Immunization Practices
(ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes
zoster: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.

 3  (#_ednref3) Steinmann et al. Risk factors for herpes zoster infections: a
systematic review and meta-analysis unveiling common trends and heterogeneity
patterns. Infection. 2024;52(3):1009-1026. doi: 10.1007/s15010-023-02156-y.
REF-224255.

 4  (#_ednref4) GSK. Data on file.

 5  (#_ednref5) Australian Institute of Health and Welfare. Shingles in
Australia. Available at:
https://www.aihw.gov.au/getmedia/759199ff-f5c8-421d-a572-aaa984a02b49/aihw-phe-236_shingles.pdf.aspx
(https://www.aihw.gov.au/getmedia/759199ff-f5c8-421d-a572-aaa984a02b49/aihw-phe-236_shingles.pdf.aspx)
. Last Accessed: November 2025.

 6  (#_ednref6) Lee C, et al. Lifetime risk of herpes zoster in the population
of Beijing, China. Public Health Pract (Oxf). 2023;5:100356.

 7  (#_ednref7) Curran D, et al. Meta-Regression of Herpes Zoster Incidence
Worldwide. Infect Dis Ther. 2022;11(1):389-403.

 8  (#_ednref8) Mueller, N.H., et al. Varicella zoster virus infection:
clinical features, molecular pathogenesis of disease, and latency. Neurologic
clinics. 2008;26(3):675-97.

 9  (#_ednref9) Johnson, R.W., et al. Herpes zoster epidemiology, management,
and disease and economic burden in Europe: a multidisciplinary perspective.
Therapeutic advances in vaccines. 2015;3(4):109-20.

 10  (#_ednref10) Bricout, H., et al. Herpes zoster-associated mortality in
Europe: a systematic review. BMC public health. 2015;15:466.

 11  (#_ednref11) Kawai, K., et al. Systematic review of incidence and
complications of herpes zoster: towards a global perspective. BMJ open.
2014;4(6).

 12  (#_ednref12) Cunningham, AL, et al. Efficacy of the Herpes Zoster Subunit
Vaccine in Adults 70 Years of Age or Older. New England Journal of Medicine.
2016;375(11):1019-32.

 13  (#_ednref13) The GSK proprietary AS01 adjuvant system contains QS-21
Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of
Agenus Inc. (NASDAQ: AGEN), MPL and liposomes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAFFFVILEIRIIR



            Copyright 2019 Regulatory News Service, all rights reserved